Predicting cumulative incidence of adverse events in older patients with cancer undergoing first-line palliative chemotherapy: Korean Cancer Study Group (KCSG) multicentre prospective study

Abstract

WHO ICTRP number, KCT0001071.

Relationship between markers of malnutrition and clinical outcomes in older adults with cancer: systematic review, narrative synthesis and meta-analysis

“…Table 1 provides a summary description of the included studies. There were 14 prospective [31][32][33][34][35][36][37][38][39][40][41][42][43][44], 24 retrospective cohort studies , 2 cross-sectional studies [69,70] and 2 RCTs [71,72]. Sample sizes ranged from 24 [39] to 12,979 [52].…”

“…All studies were based in secondary and tertiary healthcare settings; outpatient clinics; chemotherapy or radiotherapy treatments; or inpatients. [39,51,70], three biochemical markers (haemoglobin, albumin and Creactive protein [31,32,34,37,38,40,41,45,46,49,50,58,60,61,67,[69][70][71][72]; and food and fluid measures [33,35,42]. Patient outcomes included survival, mortality, chemotherapy complications (including dosereductions and toxicities), post-operative complications (including post-operative delirium [POD], functional decline and treatment modifications) and caregiver burden.…”

Predicting Chemotherapy Toxicity in Older Patients with Cancer: A Multicenter Prospective Study

“…Given that several studies have previously shown a grade 3-5 toxicity rate of 30%-50% [8][9][10][11], a conservative estimation assuming a minimum rate of grade 3-5 toxicity of 30%, with a precision of 4%, and a rate of lost patients of 10%, established a minimum sample size of 550 patients.…”

“…Although several authors have pointed out the ability of some geriatric variables to predict the development of toxicity in the older patient, such as the grip strength [39], timed up and go [18], nutritional status [10,11,40], cognition [10,18,40], IADL [10], social support [9], and others, the lack of consistency of these variables is striking among the different studies that have tried to identify predictive risk factors for chemotherapy toxicity in the older patient [41]. In fact, none of the three tools that have been proposed so far to predict toxicity in different tumors include the same geriatric variables [9][10][11]. In our series, none of the variables included in the geriatric assessment were useful to identify the risk of developing grade 3-5 toxicity as a result of chemotherapy.…”

“…Factors that influence the resistance to use chemotherapy in older patients include a general lack of studies in this age group as well as the fear that the progressive reduction of functional reserve that occurs in various organs with aging might increase the susceptibility of older patients to adverse effects and comorbidity [7]. In fact, about 30%-50% of older patients receiving chemotherapy for a solid tumor will experience a severe (grade 3-5) toxicity over the treatment course [8][9][10][11].…”